Business
Completion of ADL Health Acquisition
Completion of ADL Health Acquisition.
About this update from Ekf Diagnostics Holdings Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7207O\n EKF Diagnostics Holdings PLC\n 12 October 2021\n \n \n \n \n EKF Diagnostics Holdings plc\n \n \n (\"EKF\", the \"Company\" or the \"Group\")\n \n \n \n \n \n Completion of acquisition, Admission & TVR Update \n \n \n \n \n \n Capitalised terms in this announcement carry the same meaning as in the\nRNS of 28 September 2021, unless otherwise stated\n \n \n \n \n \n EKF Diagnostics Holdings plc \n (AIM: EKF), the AIM-listed point-of-care business\n , announces that, further to the announcement on 28 September, the Acquisition of \n ADL Health has completed.\n \n \n \n \n \n Admission of the Consideration Shares to trading on AIM and Total Voting Rights\n \n \n \n \n \n Application has been made for admission of\n \n 8,937,337 Consideration Shares to trading on the AIM Market of the London Stock Exchange (\"Admission\") based on an exchange rate of US$1.37115:£1. Admission is expected to take place on 14 October 2021.\n \n \n \n \n \n The Consideration Shares will, when issued, be credited as fully paid new ordinary shares and will rank equally in all respects with the existing ordinary shares, including the right to receive any dividend or other distribution declared, made or paid after Admission.\n \n \n \n \n \n For the purposes of the Financial Conduct Authority's Disclosure Guidance and Transparency Rules (\"DTRs\"), the issued ordinary share capital of the Company following Admission will consist of 463,930,564 ordinary shares each carrying one voting right. There are no ordinary shares held in treasury. From the date of Admission, the figure of 463,930,564 may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, the Company under the DTRs.\n \n \n \n \n \n \n \n \n For further information please contact:\n \n \n \n \n \n \n \n \n EKF Diagnostics Holdings plc\n \n \n \n \n \n www.ekfdiagnostics.com\n \n \n \n \n \n \n \n Mike Salter, CEO\n \n \n \n \n \n \n \n Via Walbrook PR\n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n Singer Capital Markets (Nominated Adviser & Joint Broker)\n \n \n \n \n \n Tel: +44 (\n 0)20 7496 3000\n \n \n \n \n \n \n Aubrey Powell...